Literature DB >> 31676574

Twist1-Induced Epithelial Dissemination Requires Prkd1 Signaling.

Dan Georgess1,2, Veena Padmanaban3, Orit Katarina Sirka3, Kester Coutinho3, Alex Choi3, Gabriela Frid3, Neil M Neumann3, Takanari Inoue3, Andrew J Ewald1,4,5.   

Abstract

Dissemination is an essential early step in metastasis but its molecular basis remains incompletely understood. To define the essential targetable effectors of this process, we developed a 3D mammary epithelial culture model, in which dissemination is induced by overexpression of the transcription factor Twist1. Transcriptomic analysis and ChIP-PCR together demonstrated that protein kinase D1 (Prkd1) is a direct transcriptional target of Twist1 and is not expressed in the normal mammary epithelium. Pharmacologic and genetic inhibition of Prkd1 in the Twist1-induced dissemination model demonstrated that Prkd1 was required for cells to initiate extracellular matrix (ECM)-directed protrusions, release from the epithelium, and migrate through the ECM. Antibody-based protein profiling revealed that Prkd1 induced broad phosphorylation changes, including an inactivating phosphorylation of β-catenin and two microtubule depolymerizing phosphorylations of Tau, potentially explaining the release of cell-cell contacts and persistent activation of Prkd1. In patients with breast cancer, TWIST1 and PRKD1 expression correlated with metastatic recurrence, particularly in basal breast cancer. Prkd1 knockdown was sufficient to block dissemination of both murine and human mammary tumor organoids. Finally, Prkd1 knockdown in vivo blocked primary tumor invasion and distant metastasis in a mouse model of basal breast cancer. Collectively, these data identify Prkd1 as a novel and targetable signaling node downstream of Twist1 that is required for epithelial invasion and dissemination. SIGNIFICANCE: Twist1 is a known regulator of metastatic cell behaviors but not directly targetable. This study provides a molecular explanation for how Twist1-induced dissemination works and demonstrates that it can be targeted. GRAPHICAL ABSTRACT: http://cancerres.aacrjournals.org/content/canres/80/2/204/F1.large.jpg. ©2019 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31676574      PMCID: PMC7448227          DOI: 10.1158/0008-5472.CAN-18-3241

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  54 in total

1.  Cancer Statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-01-05       Impact factor: 508.702

2.  Potent and selective disruption of protein kinase D functionality by a benzoxoloazepinolone.

Authors:  Elizabeth R Sharlow; Karthik V Giridhar; Courtney R LaValle; Jun Chen; Stephanie Leimgruber; Rebecca Barrett; Karla Bravo-Altamirano; Peter Wipf; John S Lazo; Q Jane Wang
Journal:  J Biol Chem       Date:  2008-09-30       Impact factor: 5.157

Review 3.  Plasticity of cell migration: a multiscale tuning model.

Authors:  Peter Friedl; Katarina Wolf
Journal:  J Cell Biol       Date:  2009-12-01       Impact factor: 10.539

4.  PKD1 phosphorylation-dependent degradation of SNAIL by SCF-FBXO11 regulates epithelial-mesenchymal transition and metastasis.

Authors:  Hanqiu Zheng; Minhong Shen; Yin-Lian Zha; Wenyang Li; Yong Wei; Mario Andres Blanco; Guangwen Ren; Tianhua Zhou; Peter Storz; Hui-Yun Wang; Yibin Kang
Journal:  Cancer Cell       Date:  2014-09-08       Impact factor: 31.743

5.  Improved outcomes from adding sequential Paclitaxel but not from escalating Doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer.

Authors:  I Craig Henderson; Donald A Berry; George D Demetri; Constance T Cirrincione; Lori J Goldstein; Silvana Martino; James N Ingle; M Robert Cooper; Daniel F Hayes; Katherine H Tkaczuk; Gini Fleming; James F Holland; David B Duggan; John T Carpenter; Emil Frei; Richard L Schilsky; William C Wood; Hyman B Muss; Larry Norton
Journal:  J Clin Oncol       Date:  2003-03-15       Impact factor: 44.544

6.  Twist, a master regulator of morphogenesis, plays an essential role in tumor metastasis.

Authors:  Jing Yang; Sendurai A Mani; Joana Liu Donaher; Sridhar Ramaswamy; Raphael A Itzykson; Christophe Come; Pierre Savagner; Inna Gitelman; Andrea Richardson; Robert A Weinberg
Journal:  Cell       Date:  2004-06-25       Impact factor: 41.582

Review 7.  The roles of TGFβ in the tumour microenvironment.

Authors:  Michael Pickup; Sergey Novitskiy; Harold L Moses
Journal:  Nat Rev Cancer       Date:  2013-10-17       Impact factor: 60.716

8.  Discovery of diverse small molecule chemotypes with cell-based PKD1 inhibitory activity.

Authors:  Elizabeth R Sharlow; Gabriela Mustata Wilson; David Close; Stephanie Leimgruber; Manuj Tandon; Robyn B Reed; Tong Ying Shun; Q Jane Wang; Peter Wipf; John S Lazo
Journal:  PLoS One       Date:  2011-10-05       Impact factor: 3.240

9.  Twist1-positive epithelial cells retain adhesive and proliferative capacity throughout dissemination.

Authors:  Eliah R Shamir; Kester Coutinho; Dan Georgess; Manfred Auer; Andrew J Ewald
Journal:  Biol Open       Date:  2016-09-15       Impact factor: 2.422

10.  High TWIST1 mRNA expression is associated with poor prognosis in lymph node-negative and estrogen receptor-positive human breast cancer and is co-expressed with stromal as well as ECM related genes.

Authors:  Muhammad Riaz; Anieta M Sieuwerts; Maxime P Look; Mieke A Timmermans; Marcel Smid; John A Foekens; John W M Martens
Journal:  Breast Cancer Res       Date:  2012-09-11       Impact factor: 6.466

View more
  9 in total

Review 1.  Regulation of breast cancer metastasis signaling by miRNAs.

Authors:  Belinda J Petri; Carolyn M Klinge
Journal:  Cancer Metastasis Rev       Date:  2020-09       Impact factor: 9.264

2.  A phase II study of efficacy, toxicity, and the potential impact of genomic alterations on response to eribulin mesylate in combination with trastuzumab and pertuzumab in women with human epidermal growth factor receptor 2 (HER2)+ metastatic breast cancer.

Authors:  Nikhil Wagle; Rachel A Freedman; Sara M Balch; Ines Vaz-Luis; Tianyu Li; Nabihah Tayob; Esha Jain; Karla Helvie; Jorge E Buendia-Buendia; Erin Shannon; Steven J Isakoff; Nadine M Tung; Ian E Krop; Nancy U Lin
Journal:  Breast Cancer Res Treat       Date:  2021-07-24       Impact factor: 4.872

3.  Organotypic culture assays for murine and human primary and metastatic-site tumors.

Authors:  Veena Padmanaban; Eloise M Grasset; Neil M Neumann; Andrew K Fraser; Elodie Henriet; William Matsui; Phuoc T Tran; Kevin J Cheung; Dan Georgess; Andrew J Ewald
Journal:  Nat Protoc       Date:  2020-07-20       Impact factor: 13.491

4.  C(3)1-TAg in C57BL/6 J background as a model to study mammary tumor development.

Authors:  Isadora F G Sena; Beatriz G S Rocha; Caroline C Picoli; Gabryella S P Santos; Alinne C Costa; Bryan O P Gonçalves; Ana Paula V Garcia; Maryam Soltani-Asl; Leda M C Coimbra-Campos; Walison N Silva; Pedro A C Costa; Mauro C X Pinto; Jaime H Amorim; Vasco A C Azevedo; Rodrigo R Resende; Debora Heller; Geovanni D Cassali; Akiva Mintz; Alexander Birbrair
Journal:  Histochem Cell Biol       Date:  2021-05-18       Impact factor: 4.304

5.  The oncogenic E3 ligase TRIP12 suppresses epithelial-mesenchymal transition (EMT) and mesenchymal traits through ZEB1/2.

Authors:  Kwok Kin Lee; Deepa Rajagopalan; Shreshtha Sailesh Bhatia; Roberto Tirado-Magallanes; Wee Joo Chng; Sudhakar Jha
Journal:  Cell Death Discov       Date:  2021-05-07

Review 6.  Organotypic Modeling of the Tumor Landscape.

Authors:  Maria M Haykal; Clara Nahmias; Christine Varon; Océane C B Martin
Journal:  Front Cell Dev Biol       Date:  2020-11-24

7.  Distinct roles of tumor associated mutations in collective cell migration.

Authors:  Rachel M Lee; Michele I Vitolo; Wolfgang Losert; Stuart S Martin
Journal:  Sci Rep       Date:  2021-05-13       Impact factor: 4.996

Review 8.  Transcriptional Factor Repertoire of Breast Cancer in 3D Cell Culture Models.

Authors:  Hande Özkan; Deniz Gülfem Öztürk; Gozde Korkmaz
Journal:  Cancers (Basel)       Date:  2022-02-17       Impact factor: 6.639

Review 9.  Small-Molecule Inhibitor Targeting Protein Kinase D: A Potential Therapeutic Strategy.

Authors:  Die Lv; Hongli Chen; Yun Feng; Bomiao Cui; Yingzhu Kang; Ping Zhang; Min Luo; Jiao Chen
Journal:  Front Oncol       Date:  2021-06-24       Impact factor: 6.244

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.